Plasmacytoid dendritic cell distribution and maturation are altered in lupus prone mice prior to the onset of clinical disease

Copyright © 2016. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 175(2017) vom: 05. Feb., Seite 109-114
1. Verfasser: Scott, Jennifer L (VerfasserIn)
Weitere Verfasser: Wirth, Jena R, EuDaly, Jackie G, Gilkeson, Gary S, Cunningham, Melissa A
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Research Support, Non-U.S. Gov't Autoimmunity Dendritic cells Rodent Systemic lupus erythematosus Interferon Type I
LEADER 01000naa a22002652 4500
001 NLM267612435
003 DE-627
005 20231224221052.0
007 cr uuu---uuuuu
008 231224s2017 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2016.12.009  |2 doi 
028 5 2 |a pubmed24n0892.xml 
035 |a (DE-627)NLM267612435 
035 |a (NLM)28041989 
035 |a (PII)S1521-6616(16)30377-1 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Scott, Jennifer L  |e verfasserin  |4 aut 
245 1 0 |a Plasmacytoid dendritic cell distribution and maturation are altered in lupus prone mice prior to the onset of clinical disease 
264 1 |c 2017 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 05.06.2017 
500 |a Date Revised 11.03.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2016. Published by Elsevier Inc. 
520 |a Plasmacytoid dendritic cells (pDCs) and their production of type I interferons (IFN) are key pathogenic mediators of systemic lupus erythematosus (SLE). Despite the key role of pDCs in SLE, the mechanism by which pDCs promote disease is not well understood. The first objective for this study was to assess the number and maturation state of pDCs in pre-disease NZM2410 lupus prone mice compared to control mice. Second, we sought to identify mechanisms responsible for the alteration in pDCs in NZM mice prior to onset of clinical disease. We compared the number and percent of pDCs in the spleens and bone marrow (BM) of pre-disease NZM24010 (NZM) mice to C57BL/6 (B6) control mice. In the spleens of pre-disease NZM mice, pDC percent and number were increased. This increase occurs in parallel with a decrease in BM pDC number and percent in the NZM mice. The decrease in BM pDC number suggests the increase in spleen pDCs is a result of altered pDC distribution and not increased production of pDCs in the BM. To determine if pDC developmental potential is altered in lupus prone mice, we cultured BM from NZM and B6 mice in vitro. We found a reduced percentage/number of pDCs developing from the BM of NZM mice compared to B6 mice, which further supports that the increase in pDC number is a result of altered pDC distribution rather than increased pDC production. To better characterize the pDC population, we compared the percentage of mature pDCs in the spleens and BM of NZM mice to controls. In the NZM mice, there is a dramatic reduction in the number of mature pDCs in the BM of NZM mice, suggesting that mature pDCs exit the BM at a higher rate/earlier maturation time compared to healthy mice. We conclude that pDCs contribution to disease pathogenesis in NZM mice may include the alteration of pDC distribution to increase the number of pDCs in the spleen prior to disease onset 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, U.S. Gov't, Non-P.H.S. 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Autoimmunity 
650 4 |a Dendritic cells 
650 4 |a Rodent 
650 4 |a Systemic lupus erythematosus 
650 7 |a Interferon Type I  |2 NLM 
700 1 |a Wirth, Jena R  |e verfasserin  |4 aut 
700 1 |a EuDaly, Jackie G  |e verfasserin  |4 aut 
700 1 |a Gilkeson, Gary S  |e verfasserin  |4 aut 
700 1 |a Cunningham, Melissa A  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 175(2017) vom: 05. Feb., Seite 109-114  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:175  |g year:2017  |g day:05  |g month:02  |g pages:109-114 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2016.12.009  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 175  |j 2017  |b 05  |c 02  |h 109-114